GRI Bio highlights IPF drug candidate GRI-0621 in “Why Now” webcast ahead of ERS 2026 data presentation

GRI•2026-08-27

Webcast highlights GRI-0621

GRI Bio highlighted its idiopathic pulmonary fibrosis drug candidate GRI-0621 in a “Why Now” on-demand investor webcast.

Management framed GRI-0621 as a once-daily oral therapy targeting inflammation, fibrosis and tissue repair to support a differentiated approach in IPF.

Data presentation scheduled for ERS 2026

New study results were not released; data are scheduled for presentation at the 2026 European Respiratory Society Congress on Sept. 5-9.

GRI Bio highlights IPF drug candidate GRI-0621 in “Why Now” webcast ahead of ERS 2026 data presentation

Webcast highlights GRI-0621

Data presentation scheduled for ERS 2026

Related News

Fitch assigns Gorilla Technology first-time B- credit rating, outlook positive

Ollie's Bargain Outlet Holdings Inc <OLLI.O>: UBS cuts target price to $85 from $87

Trinity Capital commits equipment financing to LuxWall

Credo CEO, CFO to present at Goldman Sachs Communacopia + Technology Conference

Caterpillar CEO Joe Creed to join Wells Fargo-hosted virtual investor discussion